Table III.
Association between SPARCL1 expression and vital status of patients with different tumors, in accordance with The Cancer Genome Atlas cohort.
| SPARCL1 expression | ||||
|---|---|---|---|---|
| Patient's vital status | No. of patients | Low (%) | High (%) | P-value |
| Glioma of lower grade | 528 | 0.001 | ||
| Deceased | 134 (25.4%) | 84 (62.7) | 50 (37.3) | |
| Alive | 394 (74.6%) | 180 (45.7) | 214 (54.3) | |
| Lung adenocarcinoma | 516 | 0.001 | ||
| Deceased | 187 (36.2%) | 111 (59.4) | 76 (40.6) | |
| Alive | 329 (63.8%) | 146 (44.4) | 183 (55.6) | |
| Hepatocellular carcinoma | 372 | 0.024 | ||
| Deceased | 130 (34.9%) | 75 (57.7) | 55 (42.3) | |
| Alive | 242 (65.1%) | 110 (45.5) | 132 (54.5) | |
| Cervical adenocarcinoma | 305 | 0.076 | ||
| Deceased | 73 (23.9%) | 43 (58.9) | 30 (41.1) | |
| Alive | 232 (76.1%) | 109 (47.0) | 123 (53.0) | |
| Subcutaneous melanoma | 470 | 0.42 | ||
| Deceased | 222 (47.2%) | 100 (45.0) | 122 (55.0) | |
| Alive | 248 (52.8%) | 135 (54.4) | 113 (45.6) | |
| Acute myeloid leukemia | 173 | 0.916 | ||
| Deceased | 114 (65.9%) | 57 (50.0) | 57 (50.0) | |
| Alive | 59 (34.1%) | 29 (49.2) | 30 (50.8) | |
| Lymphoma | 27 | 1 | ||
| Deceased | 6 (22.2%) | 3 (50.0) | 3 (50.0) | |
| Alive | 21 (77.8%) | 11 (52.4) | 10 (47.6) | |
| Prostate adenocarcinoma | 497 | 0.339 | ||
| Deceased | 10 (2.0%) | 7 (70.0) | 3 (30.0) | |
| Alive | 487 (98.0%) | 242 (49.7) | 245 (50.3) | |
| Sarcoma | 261 | 0.666 | ||
| Deceased | 99 (37.9%) | 51 (51.5) | 48 (48.5) | |
| Alive | 162 (62.1%) | 79 (48.8) | 83 (51.2) | |
| Esophageal carcinoma | 184 | 0.981 | ||
| Deceased | 77 (41.8%) | 38 (49.4) | 39 (50.6) | |
| Alive | 107 (58.2%) | 53 (49.5) | 54 (50.5) | |
Expression values of SPARCL1 were divided into high and low expression using the median as the threshold value. Cervical adenocarcinoma is defined as a cervical squamous cell carcinoma and endocervical adenocarcinoma. Lymphoma is defined as a lymphoid neoplasm diffuse large B-cell lymphoma. SPARCL1, SPARC-like protein 1.